Tiragolumab

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,

Abstract

A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).

Org: Rush University Cancer Center, Ideker Laboratory, Alliance Foundation Trials,

Clinical trial

A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-03-30

Clinical trial

A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Status: Active (not recruiting), Estimated PCD: 2019-08-26

Clinical trial

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Status: Recruiting, Estimated PCD: 2025-08-31

Clinical trial

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)

Status: Not yet recruiting, Estimated PCD: 2027-08-31

Clinical trial

Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Status: Recruiting, Estimated PCD: 2028-02-01

Abstract

The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients.

Org: General Hospital of Central Theater Command, Suzhou, China,

Clinical trial

DETECT V / CHEVENDO A Multicenter, Randomized Phase III Study to Compare Chemo- Versus Endocrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) Plus Kisqali® (Ribociclib) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer.

Status: Active (not recruiting), Estimated PCD: 2025-01-31

Clinical trial

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49%

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736)

Status: Active (not recruiting), Estimated PCD: 2023-09-07

Clinical trial

P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Status: Terminated, Estimated PCD: 2023-11-27

Clinical trial

A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

Status: Active (not recruiting), Estimated PCD: 2026-01-01

Clinical trial

Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer

Status: Completed, Estimated PCD: 2020-10-06

Clinical trial

A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Terminated, Estimated PCD: 2022-09-27

Clinical trial

Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

Status: , Estimated PCD: 2025-07-01

Clinical trial

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2026-01-02

Clinical trial

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Clinical trial

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Status: , Estimated PCD: 2026-01-31

Clinical trial

MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Status: Recruiting, Estimated PCD: 2027-08-15

Clinical trial

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Status: Recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.

Status: Active (not recruiting), Estimated PCD: 2030-04-01

Clinical trial

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Status: Recruiting, Estimated PCD: 2033-03-31

Clinical trial

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficacy and Safety of Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Combined With Carboplatin for High-risk, Triple-negative Early Breast Cancer

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)

Status: Withdrawn, Estimated PCD: 2026-05-31

Clinical trial

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Phase Ib/II Trial of Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-05-31

Clinical trial

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2026-10-31

Clinical trial

A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Status: Active (not recruiting), Estimated PCD: 2021-05-09

Clinical trial

DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A

Status: Active (not recruiting), Estimated PCD: 2026-01-31

Clinical trial

Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2027-08-01

Clinical trial

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Recruiting, Estimated PCD: 2026-08-30

Clinical trial

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2019-08-21

Clinical trial

Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer

Status: Completed, Estimated PCD: 2023-06-01

Clinical trial

MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

Status: Recruiting, Estimated PCD: 2027-04-30

Clinical trial

GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262

Status: Active (not recruiting), Estimated PCD: 2015-12-01

Clinical trial

Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2014-08-01

Clinical trial

A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Status: Completed, Estimated PCD: 2019-01-01

Clinical trial

A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas

Status: Recruiting, Estimated PCD: 2025-08-05

Clinical trial

Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer

Status: Recruiting, Estimated PCD: 2025-01-10

Clinical trial

Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer

Status: Completed, Estimated PCD: 2019-12-13

Clinical trial

Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-06-11

Clinical trial

A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer

Status: Recruiting, Estimated PCD: 2027-08-01

Clinical trial

Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2021-02-10

Clinical trial

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2021-11-17

Clinical trial

Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

Status: Recruiting, Estimated PCD: 2027-08-01

Clinical trial

Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2023-03-20

Clinical trial

A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2021-12-01

Clinical trial

Phase II Open-label, Single-arm Trial of Neoadjuvant Pembrolizumab With Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2027-04-01

Clinical trial

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)

Status: Active (not recruiting), Estimated PCD: 2019-12-18

Clinical trial

Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147

Status: Terminated, Estimated PCD: 2017-04-24

Clinical trial

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Status: Recruiting, Estimated PCD: 2027-08-31

Clinical trial

Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2017-11-10

Clinical trial

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3

Status: Active (not recruiting), Estimated PCD: 2018-11-29

Clinical trial

Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

Status: Terminated, Estimated PCD: 2024-04-10

Clinical trial

Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)

Status: Active (not recruiting), Estimated PCD: 2023-06-19

Clinical trial

Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Status: Recruiting, Estimated PCD: 2024-12-06

Clinical trial

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Status: Completed, Estimated PCD: 2022-08-16

Clinical trial

Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel

Status: Completed, Estimated PCD: 2022-11-19

Clinical trial

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.

Status: Completed, Estimated PCD: 2022-11-21

Clinical trial

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Status: Recruiting, Estimated PCD: 2027-02-01

Clinical trial

A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

Phase II Trial of Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-Related Oropharynx Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Pilot Study of the Safety and Feasibility of Administering Concurrent Chemotherapy and Accelerated Hypofractionated Radiation Therapy in the Treatment of Medically Inoperable T2A-T4 N0 Non-small Cell Lung Cancer.

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Status: Completed, Estimated PCD: 2022-06-16

Clinical trial

A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemotherapy in The Adjuvant Treatment of Hormone Receptor (HR) Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2018-06-01

Clinical trial

Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial

Status: Recruiting, Estimated PCD: 2025-06-29

Clinical trial

A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2016-11-18

Clinical trial

A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

Phase I Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-10-31

Clinical trial

First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Status: Recruiting, Estimated PCD: 2028-04-01

Clinical trial

A Multi-Center Phase II Trial of Individualized Adaptive De-escalated Radiotherapy Using Pre and Mid-Treatment FDG-PET/CT for HPV-related Oropharynx Cancer

Status: Active (not recruiting), Estimated PCD: 2023-05-05

Clinical trial

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Status: Recruiting, Estimated PCD: 2028-12-30

Clinical trial

A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer

Status: Completed, Estimated PCD: 2023-09-27

Clinical trial

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months

Status: Active (not recruiting), Estimated PCD: 2024-01-01

Clinical trial

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Status: Recruiting, Estimated PCD: 2024-08-31

Clinical trial

A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Status: Terminated, Estimated PCD: 2021-10-30

Clinical trial

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2025-11-20

Clinical trial

An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Status: Recruiting, Estimated PCD: 2024-12-05

Clinical trial

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2021-11-28

Clinical trial

A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings

Status: Not yet recruiting, Estimated PCD: 2027-12-01

Clinical trial

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.

Status: Active (not recruiting), Estimated PCD: 2027-11-30

Clinical trial

A Prospective, Randomized Controlled Study to Evaluate the Efficacy and Safety of Durvalumab Combined With Neoadjuvant Therapy in Patients With Local Advanced Esophageal Squamous Cell Carcinoma

Status: Completed, Estimated PCD: 2023-12-01

Clinical trial

A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics

Status: Recruiting, Estimated PCD: 2029-06-01

Clinical trial

Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches

Status: Active (not recruiting), Estimated PCD: 2016-11-01

Clinical trial

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

Status: Active (not recruiting), Estimated PCD: 2019-04-30

Clinical trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors

Status: Recruiting, Estimated PCD: 2025-10-30

Clinical trial

Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer

Status: Recruiting, Estimated PCD: 2026-12-21

Clinical trial

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Status: Completed, Estimated PCD: 2019-12-23

Clinical trial

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

Status: Not yet recruiting, Estimated PCD: 2027-07-13

Clinical trial

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

"Evaluation of the Effect of Pentoxifylline on the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

Status: Completed, Estimated PCD: 2023-09-18

Clinical trial

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Status: , Estimated PCD: 2021-02-11

Clinical trial

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Status: Recruiting, Estimated PCD: 2030-07-01

Clinical trial

A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors

Status: Completed, Estimated PCD: 2019-04-01

Clinical trial

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2021-04-01

Clinical trial

Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic Chemotherapy

Status: Completed, Estimated PCD: 2023-08-31

Clinical trial

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.

Status: Terminated, Estimated PCD: 2014-06-01

Clinical trial

DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting, Estimated PCD: 2027-01-30

Clinical trial

A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2025-08-31

Clinical trial

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Status: Active (not recruiting), Estimated PCD: 2024-03-30

Clinical trial

A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

Status: Completed, Estimated PCD: 2023-11-15

Clinical trial

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2023-01-26

Clinical trial

Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-06-15

Clinical trial

A Pilot Study of Hypoxia as a Potential Resistance Mechanism to PD-1 Checkpoint Blockade Therapy in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (HYPERION)

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer

Status: Recruiting, Estimated PCD: 2024-05-01

Clinical trial

A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients

Status: Completed, Estimated PCD: 2017-12-01

Clinical trial

Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-07-17

Clinical trial

LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2023-07-12

Clinical trial

Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2025-10-31

Clinical trial

A Single-arm, Open, Single-center, Prospective and Exploratory Clinical Study of Surufatinib Combined With Tislelizumab in the Treatment of Advanced Lung Cancer With Neuroendocrine Differentiation

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Status: Completed, Estimated PCD: 2014-04-21

Clinical trial

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Status: Recruiting, Estimated PCD: 2025-05-31

Clinical trial

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-04-30

Clinical trial

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting: A Phase 2 Clinical Trial Protocol Studying Biological Rationale for the Optimal Selection of Treatment Regimens

Status: Active (not recruiting), Estimated PCD: 2021-12-31

Clinical trial

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Status: Recruiting, Estimated PCD: 2028-10-31

Clinical trial

Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2013-12-30

Clinical trial

A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer

Status: Completed, Estimated PCD: 2007-05-01

Clinical trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Status: Recruiting, Estimated PCD: 2026-11-04

Clinical trial

A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)

Status: Active (not recruiting), Estimated PCD: 2023-12-30

Clinical trial

A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2019-01-01

Clinical trial

A Phase III Multicentre Trial of Weekly Induction Chemotherapy Followed by Standard Chemoradiation Versus Standard Chemoradiation Alone in Patients With Locally Advanced Cervical Cancer

Status: Active (not recruiting), Estimated PCD: 2026-02-01

Clinical trial

BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2026-09-27

Clinical trial

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2020-02-23

Clinical trial

LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial)

Status: Completed, Estimated PCD: 2021-07-29

Clinical trial

Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-08-01

Clinical trial

A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2027-04-01

Clinical trial

Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Status: Not yet recruiting, Estimated PCD: 2029-01-03

Clinical trial

A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Status: Active (not recruiting), Estimated PCD: 2023-02-25

Clinical trial

Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial

Status: Active (not recruiting), Estimated PCD: 2023-03-29

Clinical trial

Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer

Status: Completed, Estimated PCD: 2021-03-12

Clinical trial

A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma

Status: Terminated, Estimated PCD: 2016-08-01

Clinical trial

A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-11-21

Clinical trial

Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer

Status: Completed, Estimated PCD: 2023-01-03

Clinical trial

Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Status: Terminated, Estimated PCD: 2023-01-30

Clinical trial

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Status: Active (not recruiting), Estimated PCD: 2023-12-15

Clinical trial

A Phase II Clinical Trial of Tiragolumab in Combination With Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Status: Terminated, Estimated PCD: 2022-01-07

Clinical trial

Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC

Status: Active (not recruiting), Estimated PCD: 2019-04-16

Clinical trial

A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance

Status: Completed, Estimated PCD: 2019-08-01

Clinical trial

Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)

Status: Withdrawn, Estimated PCD: 2023-07-26

Clinical trial

A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.

Status: Completed, Estimated PCD: 2017-04-18

Clinical trial

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Status: Active (not recruiting), Estimated PCD: 2015-02-25

Clinical trial

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2024-10-21

Clinical trial

Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy

Status: Active (not recruiting), Estimated PCD: 2025-12-01

Clinical trial

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2027-12-01

Clinical trial

Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

Status: Active (not recruiting), Estimated PCD: 2014-07-15

Clinical trial

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2019-04-04

Clinical trial

Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer

Status: Completed, Estimated PCD: 2005-01-01

Clinical trial

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2006-11-01

Clinical trial

A Phase II Study of Pembrolizumab in Combination With Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial (Squamous Cell Carcinoma of Head and Neck Response-Guided Therapy)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study

Status: Recruiting, Estimated PCD: 2028-03-01

Clinical trial

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status: Terminated, Estimated PCD: 2017-08-31

Clinical trial

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of Capecitabine Plus Concomitant Radiotion Therapy Followed by Durvalumab (MEDI4736) as Preoperative Treatment in Rectal Cancer.

Status: Recruiting, Estimated PCD: 2022-11-30

Clinical trial

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2024-03-31

Clinical trial

A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Status: Recruiting, Estimated PCD: 2024-05-01

Clinical trial

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-16

Clinical trial

A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Status: Completed, Estimated PCD: 2022-11-10

Clinical trial

A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]

Status: Completed, Estimated PCD: 2023-03-12

Clinical trial

Surgical Conversion of Candonilimab (AK104) Combined With Paclitaxel, S-1 and Apatinib for Unresectable Advanced Gastric(G)/Gastroesophageal Junction(GEJ) Cancer

Status: Recruiting, Estimated PCD: 2025-03-21

Clinical trial

Phase II Trial of Pulsed Dose Chemotherapy Plus Pembrolizumab in the First Line Treatment of Recurrent/Metastatic HNSCC

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Multicenter, Open-label, Phase II Study of AK104（an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer

Status: Completed, Estimated PCD: 2024-02-28

Clinical trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Sorafenib Combined With Carboplatin/Paclitaxel and Sorafenib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer: a Single-arm, Multicenter, Exploratory Clinical Study

Status: Recruiting, Estimated PCD: 2025-10-30

Clinical trial

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2028-02-09

Clinical trial

Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma

Status: Completed, Estimated PCD: 2007-01-01

Clinical trial

A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

Status: Completed, Estimated PCD: 2021-03-31

Clinical trial

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Status: Recruiting, Estimated PCD: 2027-10-31

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Clinical trial

A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Status: Active (not recruiting), Estimated PCD: 2028-10-30

Clinical trial

Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer

Status: Completed, Estimated PCD: 2012-10-01

Clinical trial

A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-30

Clinical trial

Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)

Status: Active (not recruiting), Estimated PCD: 2023-03-11

Clinical trial

Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial

Status: Recruiting, Estimated PCD: 2024-08-10

Clinical trial

An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

Status: Active (not recruiting), Estimated PCD: 2019-05-26

Clinical trial

A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2015-01-31

Clinical trial

A Non-comparative Randomized Phase II Trial Evaluating the Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced Non-squamous NSCLC Progressing After Immunotherapy and Chemotherapy

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Status: Completed, Estimated PCD: 2023-04-18

Clinical trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Status: Not yet recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-01-07

Clinical trial

Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases

Status: Recruiting, Estimated PCD: 2026-03-15

Clinical trial

A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2023-01-21

Clinical trial

A Phase II, Randomized, Open-label Trial of Trilaciclib Prior to Chemotherapy Plus Tislelizumab as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2024-10-31

Clinical trial

A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer

Status: Terminated, Estimated PCD: 2021-03-07

Clinical trial

Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab or Pembrolizumab With Histology-Specific Chemotherapy for Operable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2025-08-27

Clinical trial

A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.

Status: Active (not recruiting), Estimated PCD: 2015-10-01

Clinical trial

Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients

Status: Completed, Estimated PCD: 2013-12-01

Clinical trial

[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Pilot Study of Induction Chemotherapy Followed by Risk and Response-Stratified Treatment for Locoregional HPV Associated Oropharyngeal Cancer

Status: Completed, Estimated PCD: 2023-01-09

Clinical trial

Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients

Status: Completed, Estimated PCD: 2013-10-01

Clinical trial

Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2019-09-01

Clinical trial

Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

Status: Terminated, Estimated PCD: 2022-09-01

Clinical trial

A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.

Status: Completed, Estimated PCD: 2018-05-03

Clinical trial

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Status: Recruiting, Estimated PCD: 2025-09-15

Clinical trial

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

Status: Recruiting, Estimated PCD: 2015-08-01

Clinical trial

A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast Cancer

Status: Recruiting, Estimated PCD: 2024-01-02

Clinical trial

Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities

Status: Recruiting, Estimated PCD: 2028-08-01

Clinical trial

A Prospective Phase Ib/II Trial of Radiotherapy Combined With Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in High-Risk Localized Soft Tissue Sarcoma (IRIS)

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study:

Status: Not yet recruiting, Estimated PCD: 2030-03-30

Clinical trial

A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx

Status: Completed, Estimated PCD: 2015-01-01

Clinical trial

A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)

Status: Completed, Estimated PCD: 2020-07-16

Clinical trial

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Status: Recruiting, Estimated PCD: 2026-05-31

Clinical trial

Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial

Status: Recruiting, Estimated PCD: 2024-11-30

Clinical trial

A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors

Status: Completed, Estimated PCD: 2023-02-23

Clinical trial

Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer

Status: Completed, Estimated PCD: 2015-12-01

Clinical trial

An Exploratory Clinical Study of Neoadjuvant Therapy With Pamiparib Combined With Surufatinib for Advanced Ovarian Cancer: A Single-arm, Prospective, Single-center Clinical Study

Status: Active (not recruiting), Estimated PCD: 2024-05-31

Clinical trial

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer

Status: Recruiting, Estimated PCD: 2024-09-18

Clinical trial

Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study

Status: Active (not recruiting), Estimated PCD: 2014-04-30

Clinical trial

A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2015-11-01

Clinical trial

Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

Status: Completed, Estimated PCD: 2017-11-01

Clinical trial

A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy

Status: Recruiting, Estimated PCD: 2030-05-31

Clinical trial

A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer

Status: Withdrawn, Estimated PCD: 2023-06-01

Clinical trial

A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Status: Recruiting, Estimated PCD: 2023-12-15

Clinical trial

PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Status: Completed, Estimated PCD: 2023-05-06

Clinical trial

A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer

Status: Completed, Estimated PCD: 2020-03-23

Clinical trial

Induction Therapy for Locally Advanced Tumor With Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Status: Not yet recruiting, Estimated PCD: 2024-05-25

Clinical trial

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Status: Completed, Estimated PCD: 2020-02-10

Clinical trial

A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

Status: Recruiting, Estimated PCD: 2025-07-18

Clinical trial

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)

Status: Recruiting, Estimated PCD: 2027-10-31

Clinical trial

Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Status: Recruiting, Estimated PCD: 2026-10-31

Clinical trial

Pilot Study of Induction Therapy Followed by Response-adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer

Status: Completed, Estimated PCD: 2015-01-01

Clinical trial

A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer

Status: Terminated, Estimated PCD: 2017-11-03

Clinical trial

Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer

Status: Completed, Estimated PCD: 2015-11-01

Clinical trial

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-30

Clinical trial

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Status: Active (not recruiting), Estimated PCD: 2026-04-30

Clinical trial

Correlation Between Early Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive and Curative Effects of Probiotics

Status: Not yet recruiting, Estimated PCD: 2023-07-01

Clinical trial

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Status: Recruiting, Estimated PCD: 2028-05-30

Clinical trial

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: the Phase 2 Solids-01 Trial

Status: Not yet recruiting, Estimated PCD: 2025-08-01

Clinical trial

Efficacy and Safety of Trilaciclib in Myeloprotection During Chemotherapy for Advanced/Recurrent Malignant Solid Tumors - A Phase II Study

Status: Not yet recruiting, Estimated PCD: 2025-09-30

Clinical trial

Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Status: Active (not recruiting), Estimated PCD: 2025-07-31

Clinical trial

A Multicenter, Open-label, Single-arm Study of Surufatinib in Combination With Tislelizumab for Second-line and Further Treatment of Metastatic Triple-negative Breast Cancer (TNBC)

Status: Not yet recruiting, Estimated PCD: 2024-08-01

Clinical trial

Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma

Status: Not yet recruiting, Estimated PCD: 2025-07-01

Clinical trial

Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer

Status: Completed, Estimated PCD: 2023-12-07

Clinical trial

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

Status: Recruiting, Estimated PCD: 2025-10-31

Clinical trial

Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Status: Completed, Estimated PCD: 2022-11-27

Clinical trial

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Status: Completed, Estimated PCD: 2023-04-24

Clinical trial

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2016-12-08

Clinical trial

Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-01-31

Clinical trial

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Recruiting, Estimated PCD: 2025-05-28

Clinical trial

Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck

Status: Completed, Estimated PCD: 2010-02-01

Clinical trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Status: Recruiting, Estimated PCD: 2034-02-21

Clinical trial

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2017-07-31

Clinical trial

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Status: , Estimated PCD: 2027-02-23

Abstract

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.

Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,

Abstract

Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

Org: University of Chicago Department of Surgery, University of Chicago Medical Center, Chicago, IL, Department of Medicine, University of Chicago, Department of Radiation and Cellular Oncology, Rush University Medical Center,

Abstract

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.

Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,

Abstract

Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).

Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,

Abstract

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).

Org: HonorHealth Research Institute, Duke Cancer Institute, Chaim Sheba Medical Center, University of Cincinnati Cancer Institute, International Drug Development Institute,

Abstract

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Org: Fred Hutchinson Cancer Research Center, University of Michigan, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, Bon Secours Cancer Institute at St. Francis, Cancer & Hematology Centers of Western Michigan,

Abstract

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Org: University of Arizona College of Medicine, European Institute of Oncology IRCCS, University of California Irvine, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Saitama Medical University International Medical Center,

Abstract

BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.

Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,

Abstract

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Org: City of Hope Comprehensive Cancer Center, Roche (China) Holding Ltd., Asan Medical Center, Genentech, Roche Products Ltd.,

Abstract

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,

Abstract

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,

Abstract

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,

Abstract

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Org: Centre Hospitalier De L Ardenne, Libramont-Chevigny, Belgium, Hospital Universitario Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Lleida, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, The Oncology Institute, Whittier, CA,

Abstract

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.

Org: Presage Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc.,

Abstract

Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.

Org: Lung Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, Heavy Ion Research Institute, Department of Thoracic and Cardiovascular Surgery,

Abstract

Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.

Org: David Geffen School of Medicine at the University of California,

Abstract

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.

Org: Memorial Sloan Kettering Cancer Center, Guy’s and St Thomas’ NHS Trust, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia "Seràgnoli", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,

Abstract

Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).

Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Cabrini Research, Malvern, Australia, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina, Linear Cancer Research and University of Western Australia, Nedlands, Western Australia, Australia,

Abstract

Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.

Org: Biocad, AV Medical Group, Saint-Petersburg, Russian Federation, Novaya klinika, Modern Medical Technologies Clinic, Altai Regional Oncology Center,

Abstract

Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.

Org: West German Study Group, Moenchengladbach, Germany, Klinikum Dortmund gGmbH, Medical School Hannover,

Abstract

Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.

Org: Medical Oncology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Laboratorio di Oncologia Traslazionale, Fondazione Arco Cuneo, Cuneo, Italy, Medical Oncology, AO S. Croce e Carle, Cuneo, Italy, Breast Unit AO S. Croce e Carle, Cuneo, Italy, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Candiolo, Italy,

Abstract

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).

Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California Comprehensive Cancer Center,

Abstract

Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).

Org: Xilis, Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc., Department of Medicine, Icahn School of Medicine at Mount Sinai,

Abstract

A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.

Org: Cairns and Hinterland Hospital and Health Service, Cancer Research South Australia (CRSA), Queen Mary Hospital, Gilead Sciences, Inc., Gilead Sciences Inc,

Abstract

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.

Org: Tianjin Medical University Cancer Hospital & Institute, Tianjin Medical university cancer institute & Hospital, Tianjin Cancer Hospital Airport Hospital,

Abstract

Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,

Abstract

Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.

Org: Garvan Institute of Medical Research, Brain and Mind Centre, The University of Sydney, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Prince of Wales Hospital,

Abstract

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.

Org: LTD High Technology Hospital Med Center, Batumi, Georgia, LLC Caucasus Medical Center, Simon Khechinashvili University Hospital, Rhizen Pharmaceuticals AG,

Abstract

A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.

Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, Fulgent Therapeutics, ANP Technologies, Inc,

Abstract

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.

Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,

Abstract

Hypersensitivity reaction to taxanes following COVID-19 vaccination.

Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,

Abstract

Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).

Org: University of Pennsylvania, Stanford Cancer Center,

Abstract

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.

Org: H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffit Cancer Center,

Abstract

Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.

Org: Breast Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service,

Abstract

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.

Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,

Abstract

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Collaborative Innovation Center for Cancer Medicine,

Abstract

Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.

Org: Tianjin Medical University Cancer Hospital & Institute, Tianjin Medical university cancer institute & Hospital, National Clinical Research Center for Cancer,

Abstract

Comprehensive characterization of androgen receptor expression in breast cancer.

Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,

Abstract

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,

Abstract

Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc).

Org: Aichi Cancer Center Research Institute, Cancer Science Institute of Singapore, National University of Singapore, Saitama Medical University International Medical Center, Hyogo Cancer Center,

Abstract

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).

Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,

Abstract

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,

Abstract

Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.

Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Clinical Research Institute at Rambam, Rambam Medical Center,

Abstract

Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).

Org: Yonsei University College of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea University College of Medicine, Seoul National University Bundang Hospital,

Abstract

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO.

Org: Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia, Calvary Mater, Newcastle, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia, Australasian Gastro-Intestinal Trials Group, Sydney, Australia, St. Vincent's Cancer Centre, Fitzroy, Australia,

Abstract

A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.

Org: Huaota Biopharma Co., Ltd., Shanghai, China, Huaota Biopharm Co., Ltd., Shanghai, China, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,

Abstract

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,

Abstract

EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.

Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,

Abstract

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.

Org: University of Texas Southwestern Medical Center, Clion - CAM Group, Cedars-Sinai Medical Center, Cancer Care Assoc-TMPN, Cancer Care Associates of York,

Abstract

Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).

Org: Jiangsu Province Hospital, Huai'an First People's Hospital, Nanjing Drum Tower Hospital, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Zhongda Hospital Southeast University,

Abstract

Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.

Org: mProbe Inc., Stanford University School of Medicine,

Abstract

Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.

Org: Comprehensive Cancer Center - Universitätsklinik für Frauenheilkunde Medizinische Universität Wien / AKH, Medical University of Vienna, Dept of OB/GYN, Karl Landsteiner Medical University, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, Department of Oncology, Medical University of Graz,

Abstract

Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).

Org: Duke University Medical Center, Mayo Clinic, Alliance Statistics and Data Management Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,

Abstract

Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?

Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,

Abstract

Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).

Org: Charité University Medicine Berlin, Department of Haematology, Lille University Hospital, Oncology and Cancer Immunology (CCM), Campus Virchow-Klinikum, Hematology Oncology Practice Eppendorf and University Cancer Center Hamburg (UCCH),

Abstract

DIRECT2: A randomized phase III trial with a fasting mimicking diet program to improve chemotherapy in patients with hormone receptor positive, HER2-negative breast cancer—A Dutch Breast Cancer Research Group study (BOOG).

Org: Leiden University Medical Center, Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China,

Abstract

Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).

Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Chicago, The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Chicago Medical Center, Chicago, IL,

Abstract

Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.

Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,

Abstract

A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.

Org: Georgetown University Medical School, Patient Advocate, Johns Hopkins University School of Medicine, Hackensack University Medical Center,

Abstract

Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of PET/CT Center, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Abstract

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.

Org: National Cancer Center, Goyang-Si, Gyeonggi-Do, South Korea, CanariaBio, Inc, Lexington, MA, CanariaBio, Inc, Singapore, Severance Hospital, Yonsei University Health System, Seoul, South Korea, John Muir Health, Walnut Creek, CA,

Abstract

Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,

Abstract

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.

Org: Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China, Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou, China,

Abstract

Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.

Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.

Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis Comprehensive Cancer Center,

Abstract

SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, First Affiliated Hospital of Gannan Medical University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The Second People's Hospital of Yibin City, Fudan University Shanghai Cancer Center,

Abstract

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.

Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Pennsylvania Health System, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center,

Abstract

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.

Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Maternal and Child Health Hospital of Jiangxi Province, Shandong Cancer Hospital & Institute, The Affiliated Tumor Hospital of Zhengzhou University, The First Affiliated Hospital of Soochow University,

Abstract

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Stanford University School of Medicine, Institute for Biometry and Clinical Epidemiology, Hospital Universitario Virgen del Rocío, Sant'Anna Hospital,

Abstract

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,

Abstract

10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.

Org: Tata Memorial Centre, Mumbai, India,

Abstract

Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.

Org: Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

Org: Shanghai East Hospital, Tongji University, Shanghai, China, Union Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Zhejiang Cancer Hospital, Chinese Academy of Sciences, West China Hospital, Sichuan University,

Abstract

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.

Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,

Abstract

A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.

Org: The Institute of Cancer Research, The Royal Marsden Hospital, University of California Irvine, UPMC Hillman Cancer Center, Sarah Cannon Cancer Institute HCA Midwest Health,

Abstract

The impact of cancer prehabilitation on psychological outcomes and quality of life in patients with gastro-oesophageal cancer.

Org: Imperial College, London Regional Cancer Center, Imperial College Healthcare NHS Trust,

Abstract

LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.

Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,

Abstract

Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.

Org: Memorial Sloan Kettering Cancer Center, Hartford Healthcare Medical Group, Hartford Healthcare Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.

Org: Beijing Tongren Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,

Abstract

A meta-analysis studying the utility of cryotherapy in the prevention of peripheral neuropathy in breast cancer patients receiving paclitaxel and nab-paclitaxel.

Org: Upstate University Hospital, SUNY Upstate Medical University, State University of New York Upstate Medical University,

Abstract

Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?

Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,

Abstract

Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi‑center, randomized, open‑label trial.

Org: Women's Hospital School of Medicine Zhejiang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Second University Hospital,

Abstract

A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.

Org: A.C. Camargo Cancer Center, Hospital de Amor de Barretos, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Liga Norte Riograndense Contra o Câncer, Centro Regional Integrado de Oncologia (CRIO),

Abstract

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.

Org: Virginia Cancer Specialists, US Oncology Network, Mirati Therapeutics, Ontada,

Abstract

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,

Abstract

Assessment of outpatient chemotherapy and unplanned emergency department visits in a large community hospital system.

Org: Orlando Health Cancer Institute,

Abstract

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).

Org: Soonchunhyang University Bucheon Hospital, Pusan National University Yangsan Hospital, Ulsan University Hospital, College of Medicine, Chungbuk National University, Seoul St. Mary's Hospital,

Abstract

Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.

Org: Catalan Institute of Oncology-Hospitalet, Hospital Josep Trueta, IDIBGi, Hospital Germans Trias i Pujol, IGTP (Health Research Institute Germans Trias i Pujol),

Abstract

Trends in utilization of first-line palliative care in non-metastatic hepatocellular carcinoma.

Org: Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center, University of Florida/UF Health Cancer Center,

Abstract

Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study.

Org: Daiichi Sankyo Inc., Basking Ridge, NJ, NJ, Cardinal Health, Dublin, Ireland,

Abstract

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.

Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,

Abstract

Homologous recombination deficiency (HRD) status to predict the efficacy and prognosis of platinum-based neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Org: Fujian Medical University Union Hospital, Amoy Diagnostics Co., Ltd.,

Abstract

Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer.

Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Juan Ramón Jiménez Hospital,

Abstract

Early taxane-induced neurotoxicity and quality of life in patients with breast cancer: A single center, retrospective study.

Org: Medical Oncolgy Unit, University Hospital and University of Cagliari, University Hospital of Cagliari,

Abstract

Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.

Org: University of Parma, Department of Molecular Medicine and Surgery, Federico II University of Naples, Cannizzaro Hospital of Catania, University Hospital of Parma,

Abstract

The use of minimal residual disease in patients with high-risk breast cancer.

Org: John A Burns School of Medicine, University of Hawaii Cancer Center,

Abstract

Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

Integrated survival analysis.

Org: Cedars-Sinai Comprehensive Cancer Center, The Angeles Clinic and Research Institute, Marymount University Hospice,

Abstract

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).

Org: College of Medicine, University of Cincinnati, Wexner Medical Center and The James Cancer Hospital, Ohio State University, Women's Cancer Care Associates, Arizona Oncology Associates, Texas Oncology - Fort Worth Cancer Center,

Abstract

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Hunan Cancer Hospital, Changsha, China, Yunnan Cancer Hospital, Kunming, China, The First Affiliated Hospital of Anhui Medical University, Hefei, China,

Abstract

A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.

Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI),

Abstract

Effect of doxorubicin on efficacy of immune checkpoint inhibitors through increasing infiltration of CD8-positive T cells and activating STAT1-IRF1-CXCL10 axis.

Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China, Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai/China, China, Department of Breast and Urinary Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, Shanghai/China, China,

Abstract

Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.

Org: Ajou University Hospital, Haeundae Paik Hospital, Uijeongbu St. Mary's Hospital, St. Vincent’s Hospital, Uijeongbu Eulji Medical Center,

Abstract

Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).

Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,

Abstract

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).

Org: Department of oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Breast Medicine, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China,

Abstract

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

Org: Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi, Japan, Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi Chuo-Ku, HYOGO-KEN, Japan, Kobe University Hospital, Kobe, Hyogo, Japan, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Hyogo, Japan, Kansai Medical University Hospital, Hirakata-Shi, Japan,

Abstract

A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.

Org: ConcertAI, Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Labcorp Drug Development Inc., Princeton, NJ,

Abstract

Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.

Org: Duke University Hospital, Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Health System,

Abstract

Deriving breast cancer chemotherapy patterns from real-world data.

Org: Thomas Jefferson University, TriNetX Europe,

Abstract

Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors.

Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, Inc.,

Abstract

Clinical and pathological description of patients with triple negative breast cancer undergoing neoadjuvant chemotherapy and pembrolizumab in a Brazilian cancer center.

Org: A.C. Camargo Cancer Center,

Abstract

Clinical predictors of survival in advanced epithelial ovarian cancer: Can we foresee the long-term survivors and develop a personalized treatment approach?

Org: Tel Aviv Sourasky Medical Center, Division of Oncology, Rambam health care, Haifa, Israel, Sourasky Medical Center, Tel Aviv, Israel, RGS Unit, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical center, Tel Aviv, Israel,

Abstract

Patient-level factors associated with the use of active surveillance: The Talking About Prostate Cancer Cohort.

Org: Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, University of California, San Francisco Department of Epidemiology and Biostatistics, San Francisco, CA, Department of Urology, Stanford University Hospital, Stanford University, Stanford, CA, Stanford University, Stanford, CA, Health Science Diligence Advisors, LLC, Redwood City, CA, Icahn School of Medicine, New York, NY, University of California San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA, Department of Social and Behavioral Sciences, University of California San Francisco, San Francisco, CA, Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco, CA, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, MD Anderson Cancer Center, Houston, TX,

Abstract

Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.

Org: Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Eisai, Exton, School of Clinical Sciences at Monash Health,

Abstract

Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.

Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,

Abstract

The polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes and the survival of triple negative breast cancer patients after platinum-based chemotherapy.

Org: Russian Medical Academy of Continuous Professional Education, Emanuel Institute of Biochemical Physics, Federal Research & Clinical Center of Physical-Chemical Medicine FMBA of Russia, Russian Cancer Research Center N.N. Blokhin, B.I. Kulakov Research National Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation,

Abstract

Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.

Org: US Biotest,

Abstract

Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.

Org: Reina Sofía University Hospital, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, CIBERONC,

Abstract

Carboplatin and paclitaxel chemoradiation for localized anal cancer in patients not eligible for mitomycin and 5-fluorouracil.

Org: University of Wisconsin Carbone Cancer Center,

Abstract

Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

The antinociceptive effects of selective TRPV1 antagonist RCI002 against chemotherapy-induced peripheral neuropathy.

Org: Rudacure, Hallym University Medical Center, Gachon University Gil Medical Center,

Abstract

Factors affecting administration of palliative care in primary central nervous system tumors: An NCDB analysis.

Org: Creighton University School of Medicine-Phoenix, Creighton Hematology Oncology, Omaha, NE,

Abstract

Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.

Org: Case Western Reserve School of Medicine, Cleveland, OH, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,

Abstract

Breaking down the divide: An analysis of male breast cancer demographics and survival by race.

Org: The Wright Center for Graduate Medical Education, University of Texas Health Science Center, Geisinger Health System Department of Pathology,

Abstract

Treatment trends and prognostic factors related to histology of squamous cell carcinoma of the prostate: A SEER review.

Org: Brody School of Medicine at East Carolina University, Vidant Health, Brody Sch Medicine at East Carolina University,

Abstract

TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Anyang Cancer Hospital, Anyang, China, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of Henan University of Science and Technology,

Abstract

The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.

Org: Linkou Chang Gung Memorial Hospital and Chang Gung University, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Chang Gung Memorial Hospital, Chang Gung University Medical College, Gynecologic Cancer Research Center,

Abstract

Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer.

Org: Invitrocue Europe AG, Invitrocue Hong Kong Ltd, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Technical University of Munich (TUM), Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China,

Abstract

Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors.

Org: MD Anderson Hematology/Oncology Fellowship, MD Anderson Cancer Center, University of Arkansas for Medical Sciences (UAMS), University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,

Abstract

High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.

Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,

Abstract

Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.

Org: Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany, Munich, Germany, Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt Am Main, Germany, Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, Städtisches Klinikum Dresden, IV. Medical Clinic, Dresden, Germany, CaritasKlinikum Saarbrücken, Klinik für Hämatologie und Onkologie, Saarbrücken, Germany,

Abstract

The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO),

Abstract

Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.

Org: CAPESESP,

Abstract

Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.

Org: Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital,

Abstract

Comparing the role of different treatment modalities in locoregionally advanced olfactory neuroblastoma: The 20-year clinical experience of a single institution.

Abstract

Prognostic and predictive significance of CA-125 elimination rate constant K (KELIM) in ovarian cancer patients treated with neoadjuvant chemotherapy in a real-world setting.

Org: Haematology- Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital - University of Athens, Medical School, National and Kapodistrian University of Athens, School of Medicine, Zhejiang University, Hangzhou, China,

Abstract

Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, open-label phase Ⅱ study (ALTN-AK105-II-06).

Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China,

Abstract

Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis.

Org: BronxCare Health System, Wayne State Univ/DMC Sinai Grace Hospital, Mount Sinai Hospital, Karmanos Cancer Institute,

Abstract

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Org: Centre François Baclesse, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Centre Léon Bérard, Hospital Universitario Reina Sofia de Cordoba, GEICO,

Abstract

Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.

Org: Istanbul University Institute of Oncology, Basaksehir Cam and Sakura City Hospital,

Abstract

An evaluation of cisplatin, doxorubicin, and cyclophosphamide (PAC) compared to other regimens for patients with unresectable or metastatic thymic carcinoma: A single-institution retrospective analysis.

Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,

Abstract

The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.

Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,

Abstract

Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.

Org: Adlai Nortye USA Inc., Adlai Nortye Biopharma, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milan, and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy,

Abstract

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China, Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China, Pathology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,

Abstract

Chronotherapy in head and neck cancer (HNC): A systematic review.

Org: Rutgers-Trinitas Regional Medical Center, Faculty of Dental Medicine and Oral Health Sciences, McGill University, Faculty of Dentistry, Dalhousie University, Faculty of Dentistry, University of Toronto, College of Dental Medicine, QU Health, Qatar University,

Abstract

Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs).

Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, Thoracic and GI Malignancies Branch, Center for Cancer Research and Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, Promontory Therapeutics Inc., New York, NY,

Abstract

Head and neck embryonal rhabdomyosarcoma clinical outcomes determinates: A pooled database analysis.

Org: Louisiana State University Health Sciences-Shreveport, LSUHSC-S/Overton Brooks VAMC, Feist-Weiller Cancer Center at LSUHSC-Shreveport,

Abstract

Survival trends among patients with mesothelioma: Impact of initial therapy at academic centers.

Org: Mayo Clinic, Jacksonville, FL,

Abstract

Demographic and racial characteristics, and survival trends in pleural mesothelioma: A population based study.

Org: Albert Einstein Medical Center, The Wright Center for Graduate Medical Education, Albert Einstein Healthcare Network,

Abstract

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).

Org: Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Jiading Central Hospital, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi Branch of Ruijin Hospital,

Product

Product

Product

Product

Product

NC410 + pembrolizumab

Product

Ramucirumab + Paclitaxel

Product

Standard-of-care chemotherapy

Product

Durvalumab + Tremelimumab + Paclitaxel + Carboplatin

Product

anthracycline plus taxane CT (triweekly AC followed by weekly paclitaxel) + triweekly 5-day FMD cycles

Product

pembrolizumab + carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide

Product

Taxanes

Product

CCRT combined with PG2

Product

Capecitabine plus ramucirumab

Product

serplulimab, (nab-) paclitaxel, carboplatin

Product

dostarlimab + carboplatin-paclitaxel

Product

carboplatin + paclitaxel + durvalumab placebo followed by durvalumab placebo + olaparib placebo

Product

Inetetamab, Pertuzumab, Paclitaxel, Carboplatin

Abstract

Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy.

Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Jacksonville, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University of Texas MD Anderson Cancer Center, Houston, TX,

Product

Standard treatment without secondary cytoreduction

Product

pembrolizumab, paclitaxel, cisplatin

Product

fruquintinib plus paclitaxel

Product

Fruquintinib + Paclitaxel

Product

tislelizumab, carboplatin, albumin-bound paclitaxel

Product

ramucirumab plus FOLFIRI